Entries by awp-admin

Corporate Headquarters Relocates

The FRI Corporate Headquarters has moved its office to the Social Research Center site effective November 1, 2009. The new address is 1040 Park Avenue, Suite 103, Baltimore, MD 21201. The phone number is 410-837-3977 and the fax number is 410-752-4218. The main email address remains the same at FRI@friendsresearch.org.

FRI Researcher Involved with Chronic Pain Treatment

Friends Research Institute via Dr. Frank Vocci was recently involved in the development of case-based activity regarding opioid therapy in primary care and chronic pain. Below are descriptions of the activities. Description of Internet Activity A Case-Based Approach to the Safe and Effective Use of Opioid Therapy in Primary Care This CME/CE case activity was developed by […]

FRI Researcher Receives Loan Repayment Award

FRI is pleased to announce that Monique Wilson, Dr.P.H., a Research Scientist at the Social Research Center, has received an award from the National Institutes of Health’s (NIH) Loan Repayment Program. In exchange for a two-year commitment to a research career with FRI, NIH will repay up to $35,000 per year of Dr. Wilson’s qualified […]

FRI Researcher Receives NIH Loan Repayment Award A Second Time

FRI is pleased to announce that Steven B. Carswell, Ph.D., Research Scientist/Vice President, has received an award from the National Institutes of Health’s (NIH) Loan Repayment Program (LRP). Dr. Carswell’s LRP award is funded through the NIH’s National Center on Minority Health and Health Disparities (NCMHD) and focuses on health disparities research. The purpose of the […]

Second FRI Researcher to Receive NIH Stimulus Funding

Friends Research Institute (FRI) was recently awarded a highly coveted challenge research grant funded through the National Institute on Drug Abuse from the American Recovery and Reinvestment Act of 2009. The nearly $1,000,000 grant award will support the work of ten research staff as well as the work of three clinics in conducting the study. […]

FRI Researcher Among First to Receive NIH Stimulus Funding

A Friends Research Institute research scientist, Dr. Timothy Kinlock is among the first in the nation to receive National Institutes of Health stimulus funding through the American Recovery and Reinvestment Act of 2009. The two-year, approximately $1,000,000 grant will support at least seven jobs and the research of investigators in Baltimore who will be collaborating […]

FRI Researcher Receives Loan Repayment Award A Second Time

FRI is pleased to announce that Michael S. Gordon, D.P.A., a Research Scientist at the Social Research Center, has received an award from the National Institutes of Health’s (NIH) Loan Repayment Program. This is the second time that Dr. Gordon has received this award. In exchange for a one-year commitment to a research career with FRI, […]

New Appointment to Board of Directors

FRI is pleased to announce the appointment of Wallace B. Pickworth, Ph.D. to its Board of Directors. Dr. Pickworth is a pharmacologist with over 30 years of preclinical and clinical experience. He has served as the Principal Investigator/Senior Project Director on various projects for the National Institute on Drug Abuse and the private pharmaceutical industry […]

FRI Researcher Accepted Into Behavioral and Social Science Volunteer Program

FRI is pleased to announce that Shannon Gwin Mitchell, Ph.D., a Research Scientist at the Social Research Center, has been accepted into the Behavioral and Social Science Volunteer Program (BSSV). The BSSV program is a national HIV prevention technical assistance program directed by the American Psychological Association, Office on AIDS. It is funded by the […]

Buprenorphine-Naloxone Puerto Rico Study Highlighted in NIDA NewsScan

FRI is pleased to announce that the results of a collaborative study between researchers in Puerto Rico and the Social Research Center, including Timothy W. Kinlock, Ph.D., Michael S. Gordon, D.P.A., and Robert P. Schwartz, M.D., were recently published in a NIDA NewsScan. This study tested whether treatment with buprenorphine-naloxone could feasibly be initiated with […]